Gene info: ID 154214

Gene: RNF217

GENE ID: 154214

Synonyms: C6orf172|IBRDC1|OSTL|dJ84N20.1

Description: ring finger protein 217

Gene type: protein-coding

Location: 6q22.31

dbXrefs: Ensembl:ENSG00000146373 Vega:OTTHUMG00000015504 UniprotKB:Q8TC41

RefSeq: NC_000006.12

Retrived from: SNP Mapped

SNPs: 2 ANCO-SNPs

Phenotype: ND|AD

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 5.552e-1 (AD) 1.320e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs571846	chr6:125080418 (GRCh38.p7)	C>T	alcohol dependence	SNV(Single Nucleotide Variation)
rs9321013	chr6:125009775 (GRCh38.p7)	G>A	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MIER3	0.866
NUP160	0.861
LMAN1	0.849
SLC30A7	0.848
DESI2	0.843
MAP3K2	0.841
PRRC1	0.84
SMC5	0.837
PGM3	0.834
PKN2	0.833

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.392
OR4F29	-0.358
LYPD8	-0.275
HES5	-0.261
CRH	-0.25
CYP1A1	-0.236
NANOS3	-0.228
NPAS1	-0.212
SPRR2A	-0.212
CRYBA2	-0.209

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C051246	1-methylanthracene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of RNF217 mRNA	28329830
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C487081	belinostat	belinostat results in increased expression of RNF217 mRNA	26272509
C487081	belinostat	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C006780	bisphenol A	bisphenol A affects the expression of RNF217 mRNA	21786754
C006780	bisphenol A	bisphenol A results in decreased expression of RNF217 mRNA	27685785
C006780	bisphenol A	bisphenol A affects the expression of RNF217 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of RNF217 gene	28505145
D016572	Cyclosporine	Cyclosporine results in increased expression of RNF217 mRNA	25562108
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of RNF217 mRNA	24317228
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of RNF217 mRNA	21266533
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of RNF217 mRNA	27392435
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF217 mRNA	22079256
C007738	fluoranthene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of RNF217 mRNA	28329830
D017313	Fenretinide	Fenretinide results in decreased expression of RNF217 mRNA	28973697
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of RNF217 mRNA	25613284
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of RNF217 mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of RNF217 mRNA	27392435
C045463	leflunomide	leflunomide results in increased expression of RNF217 mRNA	24136188
C042720	mercuric bromide	mercuric bromide results in increased expression of RNF217 mRNA	26272509
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of RNF217 mRNA	28001369
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of RNF217 mRNA"	25620056
C022838	nickel chloride	nickel chloride affects the expression of RNF217 mRNA	22110744
D010100	Oxygen	Oxygen deficiency results in increased expression of RNF217 mRNA	20880076
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
C496932	panobinostat	panobinostat results in increased expression of RNF217 mRNA	26272509
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in increased expression of RNF217 mRNA	28973697
D010634	Phenobarbital	Phenobarbital affects the expression of RNF217 mRNA	23091169
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of RNF217 mRNA	26272509
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF217 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of RNF217 mRNA	22079256\|2271453
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of RNF217 mRNA	23608068
D011441	Propylthiouracil	Propylthiouracil results in increased expression of RNF217 mRNA	24780913
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of RNF217 mRNA	24680724
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of RNF217 mRNA	19933214
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of RNF217 mRNA	25613284
C012589	trichostatin A	trichostatin A results in increased expression of RNF217 mRNA	24935251\|2627250
C057693	troglitazone	troglitazone results in decreased expression of RNF217 mRNA	28973697
D014635	Valproic Acid	Valproic Acid affects the expression of RNF217 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of RNF217 mRNA	23179753\|2438349

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004842	ubiquitin-protein transferase activity	-	EXP	19028597
GO:0004842	ubiquitin-protein transferase activity	-	ISS	-
GO:0004842	ubiquitin-protein transferase activity	-	TAS	-
GO:0031624	ubiquitin conjugating enzyme binding	-	IBA	21873635
GO:0046872	metal ion binding	-	IEA	-
GO:0061630	ubiquitin protein ligase activity	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000209	protein polyubiquitination	-	IBA	21873635
GO:0000209	protein polyubiquitination	-	TAS	-
GO:0006511	ubiquitin-dependent protein catabolic process	-	ISS	-
GO:0032436	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000151	ubiquitin ligase complex	-	IBA	21873635
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005829	cytosol	-	TAS	-
GO:0016021	integral component of membrane	-	IEA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-168256	Immune System	TAS
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation	TAS
R-HSA-983169	Class I MHC mediated antigen processing & presentation	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal